those that failed to bind one of the single substituted analogs. The (2, 3) , and treatment of patients with anti-CD4 antibodies can ameliorate the disease (4) . The higher frequency of certain histocompatibility antigens (HLA-B8, DR3) in MG patients (5) suggests a defect of immunoregulation that might be expressed at the level of antigen-major histocompatibility complex (MHC)-T-cell interactions.
Previous reports from our laboratory demonstrated that peripheral blood lymphocytes (PBLs) of 73% and 56% of MG patients proliferated in response to peptides p195-212 and p257-269, respectively. These peptides represent sequences of the human AChR a subunit (hAChRa; ref. 6 ). The response to these peptides was both significantly greater in MG patients than in healthy controls and correlated with HLA-DR11 and HLA-DR3, respectively, indicating that certain peptides of
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AChR are particularly immunogenic for certain HLA-DR types (6) . Furthermore, using a technique previously developed in our laboratory (7), we have shown that the myasthenogenic peptides were bound to HLA-DR and DQ determinants on the surface of antigen presenting cells (APCs) of MG patients and that binding was correlated with the proliferative potential of their lymphocytes (8) . Several (1996) Ala-207/Lys-262, and Lys-262/Ala-207 (25 AiM). Phycoerythrin streptavidin staining (0.5 iAg) was followed as described. Thereafter cells were subjected to flow cytometric analysis.
of Ala-207/Lys-262 and Lys-262/Ala-207, respectively (n = 24; P < 0.0001 vs. p195-212 only). Table 3 summarizes the inhibitory capacity of the single and dual analogs on p259-271-induced stimulation of PBLs of MG patients. Analog Lys-262 inhibited the stimulatory activity of p259-271 in 27 MG patients of 28 responders that were tested in the inhibition studies. For example, the mean SI of responders for proliferation of PBL to p259-271 was 3.2 and 1.3 in the absence and presence of analog Lys-262, respectively (n = 20; responders tested to p259-271, respectively (Table 3) . For example, the mean SI of responders for proliferation of PBL (11) (12) (13) . In contrast, the two epitopes used in the present study were capable of preferentially stimulating PBLs of 82% of MG patients as opposed to PBLs of healthy controls (ref. 6 and the present study). Moreover, it has been reported that a significant portion of another population of MG patients responded to peptide p257-269 (14) . Thus, these two peptides may be immunodominant epitopes of the hAChRa, whereas other epitopes described in the literature may be cryptic epitopes. The (17, 18) . Alternatively, some of the TCR antagonists may transduce a differential signal upon interaction with the TCR and render the T-cell anergic (19) . Moreover, TCR antagonists have been shown to block T-cell activation at concentrations 1000-to 10,000-fold less than required to competitively inhibit peptide binding to MHC class II determinants (20) .
The feasibility of using TCR antagonists as modulators of autoimmune diseases was tested by some groups in experimental models: A pool of two single substituted analogs of peptide 139-151 of myelin proteolipid protein was shown to inhibit induction of experimental allergic encephalomyelitis (EAE). The TCR antagonist pool was 10-fold more potent than each analog alone (21) . Alternatively, one analog with two different substitutions also was capable of blocking the induction of EAE and preventing clinical disease progression if administered at the first signs of disease (22) . In both cases, a small number of analogs could block the response, even when a diverse TCR repertoire was used (21, 22 
